Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma(DLBCL) Patient Achieve Complete Remission

### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission

DLBCL

#CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine

In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about the potential and efficacy of China’s CAR-T therapy for treating relapsed and refractory lymphomas.

Patient Treatment Journey

This Chinese patient was diagnosed with non-germinal center subtype DLBCL with TP53 gene deletion in March 2023, and his condition was assessed as high-risk. This genetic factor often complicates prognosis. The patient initially underwent treatments including R-CHOP and R-DA-EPOCH regimens, achieving partial remission (PR). Despite completing autologous stem cell transplantation (ASCT), his disease unfortunately progressed two months later, indicating that ASCT alone was insufficient for sustained remission, and the disease was on the brink of relapse.

Personalized Application of Chinese CAR-T Therapy

In desperation, the patient turned to our Advanced Medicine in China team for assistance. Under the guidance of lymphoma experts experienced in this treatment, the medical team decided to apply Chinese CAR-T cell therapy as a solution. Following a comprehensive assessment, including a detailed analysis of the patient’s medical history and genetic profile, a personalized treatment plan was devised. To further control the disease, the patient received localized retroperitoneal radiotherapy in January 2024, followed by the infusion of Chinese CAR-T cells in February after pretreatment with the FC regimen. Remarkably, just one month after the CAR-T cell infusion, the patient tolerated the therapy well and achieved complete remission (CR). This outcome not only halted disease progression but enabled the patient to return to work and resume a normal life.

Expert Interview with the Advanced Medicine in China Team

The team’s expert highlighted that this case involved relapsed refractory DLBCL, with TP53 deletion adding a higher risk of recurrence. ASCT alone was insufficient for sustained remission, making CAR-T a more effective option. Despite the greater treatment challenges, Chinese CAR-T therapy proved ideal for this high-risk relapsed case. The doctor advised that, when feasible in primary healthcare settings, Chinese CAR-T should be considered as an early intervention option. Research data supports the effectiveness of Chinese CAR-T in second-line therapy compared to standard ASCT.

Overall Advantages of Chinese CAR-T Therapy

This successful case is not isolated; it demonstrates China’s growing expertise and capabilities in CAR-T cell therapy. China has been at the forefront of research and clinical application in this field, committed to improving outcomes for lymphoma patients. The Chinese medical community takes a comprehensive approach to CAR-T therapy, prioritizing personalized medicine and tailoring treatment plans based on each patient’s unique genetic and clinical characteristics. For instance, advanced genetic testing enables doctors to identify specific mutations, such as P53 deletion, and adjust treatment strategies accordingly. When conventional chemotherapy and targeted drugs have limited efficacy, CAR-T cell therapy is increasingly being used as a viable alternative. Furthermore, Chinese hospitals continuously optimize treatment protocols. The pretreatment regimen prior to CAR-T cell infusion is meticulously designed to create an optimal therapeutic environment in the patient’s body. This not only removes barriers for the proliferation and effective functioning of CAR-T cells but also minimizes potential side effects. In this case, the patient’s positive response to the therapy was partly due to the carefully crafted pretreatment regimen.

Global Significance of China’s Experience

As the world seeks innovative cancer treatment solutions, China’s success with CAR-T cell therapy for lymphoma patients provides valuable insights. The combination of advanced medical technology, personalized treatment strategies, and comprehensive patient support offers beneficial lessons for the global fight against lymphoma and other cancers. With ongoing research and accumulating clinical experience, the future of Chinese CAR-T cell therapy holds great promise, bringing hope not only to patients in China but to patients worldwide.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaMedicalInnovation #Immunotherapy #GeneTherapy #Oncology #TP53 #CompleteRemission #AdvancedMedicine #GlobalHealth

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago patient story , CAR-T

The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!

### The Courage to Be First: China’s CAR-T Pioneer, “Emily of China,” Celebrates 6 Years in Complete Remission!

Patient Story

#CART #PatientStory #lymphoma #TP53 #DLBCL #CARTTherapy

Meet Mrs. Qin, a true fighter and the first brave patient in China to receive Fosun Kite’s Axicabtagene Ciloleucel in a CAR-T clinical trial. Her story is one of hope, perseverance, and the power of innovation.

In early 2017, a routine check-up uncovered a small lump in her neck, leading to a diagnosis of diffuse large B-cell lymphoma (DLBCL) with a TP53 gene mutation—a high-risk condition. After enduring 12 rounds of grueling chemotherapy, the cancer still returned. Just when hope seemed to be fading, Mrs. Qin became the first patient in China to join a groundbreaking CAR-T therapy trial at Ruijin Hospital under the care of Dr. Zhao Weili. She was a pioneer, much like Emily Whitehead in the U.S., the world’s first pediatric patient to receive CAR-T therapy.

Mrs. Qin recalls the challenging days of her treatment, which involved high fevers and fatigue, yet the unwavering support of Dr. Zhao’s team helped her push through. The cutting-edge CAR-T treatment not only controlled the tumor but led her into complete remission. Six years later, she remains cancer-free and now serves as a volunteer at the hospital, inspiring others who are fighting the same battle.

During the first “CAR-T Therapy Survivor Conference” in Wuhan of China, Mrs. Qin took the stage to share her emotional journey. Her story moved everyone in attendance, from fellow patients to medical experts, as she expressed gratitude for the love and care she received. “Ruijin Hospital is not just where I found a new lease on life, but a home filled with compassion and world-class medical expertise,” she shared.

Mrs. Qin’s tale of courage is a beacon of hope for those still battling the disease. Her message is simple: “No matter how tough the road, never lose faith. After every storm, the rainbow will appear.”

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChinaCAR-T #CAR-TTherapy #CancerSurvivor #MedicalBreakthrough #FosunKite #DLBCL #CancerRemission #InnovativeMedicine #HopeHealing #RuijinHospital #ChineseMedicalPioneers #PatientStories #EmilyofChina